Pantoprazole cyclodextrin inclusion complexes
An inclusion complex formed from pantoprazole and cyclodextrin is described.
1 . Inclusion complex formed of element A and element B, wherein element A is chosen from pantoprazole, a solvate of pantoprazole, a hydrate of pantoprazole, a salt of pantoprazole with a base, a solvate of a salt of pantoprazole with a base, a hydrate of a salt of pantoprazole with a base, an enantiomer of pantoprazole, a solvate of an enantiomer of pantoprazole, a hydrate of an enantiomer of pantoprazole, a salt of an enantiomer of pantoprazole, a solvate of a salt of an enantiomer of pantoprazole, a hydrate of a salt of an enantiomer of pantoprazole, or a mixture thereof; and wherein element B is chosen from cyclodextrin, a hydrate of cyclodextrin, a derivative of cyclodextrin or a mixture thereof.
2 . Inclusion complex according to claim 1 wherein element A is chosen from pantoprazole sodium sesquihydrate (=pantoprazole sodium×1.5 H 2 O), (−)-pantoprazole sodium sequihydrate, pantoprazole magnesium dihydrate or a mixture thereof.
3 . Inclusion complex according to claim 1 , wherein element B is β-cyclodextrin.
4 . Method of preparing an inclusion complex according to claim 1 comprising reacting element A with element B in a suitable solvent.
5 . Method according to claim 4 , wherein the solvent is ethanol.
6 . Inclusion complex prepared by the method according to claim 4 .
7 . Inclusion complex according to claim 1 , which is a 1/1 inclusion complex.
8 . Administration form comprising an inclusion complex according to claim 1 together with a suitable pharmaceutical auxiliary.
9 . (canceled)
10 . Method of treating or preventing a condition treatable or preventable with a pyridine-2ylmethylsulfinyl-1H-benzimidazole, which comprises administering to a subject prone to or afflicted with a condition a pharmaceutically acceptable administration form according to claim 8 comprising therapeutically effective amount of the inclusion complex.
11 . Inclusion complex according to claim 2 wherein element B is β-cyclodextrin.
12 . Method of preparing an inclusion complex according to claim 1 comprising reacting element A with element B in a suitable solvent.
13 . Method of preparing an inclusion complex according to claim 3 comprising reacting element A with element B in a suitable solvent.
14 . Administration form comprising an inclusion complex according to claim 2 together with a suitable pharmaceutical auxiliary.
15 . Administration form comprising an inclusion complex according to claim 3 together with a suitable pharmaceutical auxiliary.